IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease

Abstract Background and Aims Following induction/maintenance treatment in the UNITI/IM-UNITI studies of ustekinumab for Crohn’s disease, patients entered a long-term extension for up to 5 years from induction. Efficacy through 152 and safety through 156 weeks are reported. Methods At IM-UNITI Week 4...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Crohn's and colitis 2020-01, Vol.14 (1), p.23-32
Hauptverfasser:	Hanauer, Stephen B, Sandborn, William J, Feagan, Brian G, Gasink, Christopher, Jacobstein, Douglas, Zou, Bin, Johanns, Jewel, Adedokun, Omoniyi J, Sands, Bruce E, Rutgeerts, Paul, de Villiers, Willem J S, Colombel, Jean-Frédéric, Ghosh, Subrata
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!